Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00679939 · ClinicalTrials.gov registry record · Phase 4

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

A Phase 4 study of Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
226
Enrollment target
20
Study locations

NCT00679939 is a Phase 4 study of Diabetes Mellitus, Type 2 that has completed, run by GlaxoSmithKline. The registered enrollment target is 226 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00679939, a Phase 4 study of Diabetes Mellitus, Type 2, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
226 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG Metformin
  • DRUG Rosiglitazone

Study Locations (20)

California

  • GSK Investigational Site - Huntington Park
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - Torrance
  • GSK Investigational Site - Vista

Florida

  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami

New Mexico

  • GSK Investigational Site - Albuquerque
  • GSK Investigational Site - Albuquerque

New York

  • GSK Investigational Site - East Syracuse
  • GSK Investigational Site - Kingston

South Carolina

  • GSK Investigational Site - Columbia
  • GSK Investigational Site - Columbia

Arizona

  • GSK Investigational Site - Tucson

Kentucky

  • GSK Investigational Site - Lexington

Louisiana

  • GSK Investigational Site - Slidell

Trial Details

FieldValue
Enrollment Target 226 participants
Start Date 2008-04-21
Est. Completion 2010-09-16
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00679939

The ClinicalTrials.gov registry entry for NCT00679939 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.

NCT00679939 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, New Mexico.

Frequently Asked Questions

What is clinical trial NCT00679939 about?

NCT00679939 is a clinical study titled "Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health". The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus

What is the current status of trial NCT00679939?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2008-04-21. Estimated completion is 2010-09-16.

What conditions does trial NCT00679939 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00679939?

The interventions under investigation include: Metformin (DRUG), Rosiglitazone (DRUG).

Who is sponsoring clinical trial NCT00679939?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00679939 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.